Copper in Alzheimer's disease: too much or too little?

Expert Review of Neurotherapeutics

Volumn 9, Issue 5, 2009, Pages 631-637

  Quinn, Joseph F ^a   Crane, Susanne ^a   Harris, Christopher ^a   Wadsworth, Teri L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Animal model; Chelation; Clinical trial; Copper; Oxidative damage

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHELATING AGENT; CLIOQUINOL; COPPER; PBT2; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; UNCLASSIFIED DRUG; ZINC; ZINC ACETATE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COPPER DEFICIENCY; DRUG DOSE TITRATION; DYSTONIA; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; REVIEW; SPINAL CORD DISEASE; WILSON DISEASE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; RISK FACTORS;

EID: 66249101638     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.27     Document Type: Review

References (54)

1. Brewer GJ. The risks of free copper in the body and the development of useful anticopper drugs. Curr. Opin. Clin. Nutr. Metab. Care 11(6), 727-732 (2008).
2. Brewer GJ. Copper in medicine. Curr. Opin. Chem. Biol. 7(2), 207-212 (2003).
3. Brewer GJ, Askari FK. Wilson's disease: clinical management and therAβy.J. Hepatol. 42(Suppl. 1), S13-S21 (2005).
4. Brewer GJ, Hedera P, Kluin KJ et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therAβy in a total of 55 neurologically affected patients and follow-up with zinc therAβy. Arch. Neurol. 60(3), 379-385 (2003).
5. Brewer GJ, Askari F, Lorincz MT et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol. 63(4), 521-527 (2006).
6. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opin. Pharmacother. 2(9), 1473-1477 (2001).
7. Cheah DM, Deal YJ, Wright PF et al. Heterozygous tx mice have an increased sensitivity to copper loading: implications for Wilson's disease carriers. Biometals 20(5), 751-757(2007).
8. Kumar N, Low PA. Myeloneuropathy and anemia due to copper malabsorption. J. Neurol. 251(6), 747-749 (2004).
9. Kumar N, Crum B, Petersen RC, Vernino SA, Ahlskog JE. Copper deficiency myelopathy. Arch. Neurol. 61(5), 762-766 (2004).
10. Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 63(1), 33-39 (2004).
11. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin. Proc. 81(10), 1371-1384(2006).
12. Gambling L, Andersen HS, McArdle HJ. Iron and copper, and their interactions during development. Biochem. Soc. Trans. 36(Pt6), 1258-1261 (2008).
13. Maynard CJ, CAβpai R, Volitakis I et al. Overexpression of Alzheimer's disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277(47), 44670-44676 (2002).
14. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therAβeutics. Science 297(5580), 353-356 (2002).
15. Phinney AL, Drisaldi B, Schmidt SD et al. In vivo reduction of amyloid-β by a mutant copper transporter. Proc. Natl Acad. Sci. USA 100(24), 14193-14198 (2003).
16. Bayer TA, Schafer S, Simons A et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in AβP23 transgenic mice. Proc. Natl Acad. Sci. USA 100(24), 14187-14192 (2003).
17. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-β precursor protein gene.J. Biol. Chem. 279(19), 20378-20386 (2004).
18. Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 100(19), 11065-11069 (2003).
19. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush Al. Trace metal contamination initiates the Aβparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Aβ peptides. J. Biol. Inorg. Chem. 9(8), 954-960 (2004).
20. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rAβidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3), 665-676 (2001).
21. Opazo C, Huang X, Cherny RA et al. Metalloenzyme-like activity of Alzheimer's disease β-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J. Biol. Chem. 277(43), 40302-40308 (2002).
22. Puglielli L, Friedlich AL, Setchell KD et al. Alzheimer disease β-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 115(9), 2556-2563 (2005).
23. Crouch PJ, Blake R, Duce JA et al. Copper-dependent inhibition of human cytochrome C oxidase by a dimeric conformer of amyloid-β142. J. Neurosci. 25(3), 672-679(2005).
24. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therAβy in Alzheimer's disease. J. Alzheimers Dis. 6(3), 291-301 (2004).
25. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of P-sheets of Aβ-42 in senile plaque cores in Alzheimer's disease. J. Alzheimers Dis. 10(2-3), 173-177 (2006).
26. Khan A, Dobson JP, Exley C. Redox cycling of iron by Aβ42. Free Radic. Biol. Med. 40, 557-569 (2006).
27. Schuessel K, Schafer S, Bayer TA et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in AβP transgenic mice. Neurobiol. Dis. 18(1), 89-99 (2005).
28. Treiber C, Simons A, Strauss M et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease.J. Biol. Chem. 279(50), 51958-51964 (2004).
29. White AR, Du T, Laughton KM et al. Degradation of the Alzheimer disease amyloid P-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281(26), 17670-17680 (2006).
30. Cater MA, Mclnnes KT, Li QX et al. Intracellular copper deficiency increases amyloid-β secretion by diverse mechanisms. Biochem. J. 412(1), 141-152 (2008).
31. Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J. Inorg. Biochem. 98(12), 2160-2167(2004).
32. Brewer GJ, Dick RD, Grover DK et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin. Cancer Res. 6(1), 1-10 (2000).
33. Wadsworth TL, Bishop JA, Domes CM, Ralle M, Brewer G, Quinn JF. Copper complexing with tetrathiomolybdate in a murine model of Alzheimer's disease. Society for Neuroscience Abstracts (2007).
34. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress.J. Neurol. Sci. 143(1-2), 137-142 (1996).
35. Loeffler DA, LeWitt PA, Juneau PL et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738(2), 265-274 (1996).
36. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques.J. Neurol. Sci. 158(1), 47-52 (1998).
37. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and x-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer's disease.J. Struct. Biol. 155(1), 30-37 (2006).
38. Connor JR, Tucker P, Johnson M, Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci. Lett. 159(1-2), 88-90(1993).
39. Squitti R, Barbati G, Rossi L et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau. Neurology 67(1), 76-82 (2006).
40. CAβo CR, Arciello M, Squitti R et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 21(3), 367-372 (2008).
41. Molina JA, Jimenez-Jimenez FJ, Aguilar M V et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural Transm. 105(4-5), 479-488(1998).
42. Squitti R, Lupoi D, Pasqualetti P et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 59(8), 1153-1161 (2002).
43. Squitti R, Pasqualetti P, Cassetta E et al. Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology 60(12), 2013-2014 (2003).
44. Squitti R, Pasqualetti P, Dal Forno G et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64(6), 1040-1046 (2005).
45. Squitti R, Ventriglia M, Barbati G et al. 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J. Neural Transm. 114(12), 1589-1594 (2007).
46. Pajonk FG, Kessler H, Supprian T et al. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J. AlzheimersDis. 8(1), 23-27 (2005).
47. Kessler H, Pajonk FG, Meisser P et al. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.J. Neural Transm. 113(11), 1763-1769 (2006).
48. Ritchie CW, Bush Al, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol. 60(12), 1685-1691 (2003).
49. Tabira T. Clioquinol's return: cautions from JAβan. Science292(5525), 2251-2252 (2001).
50. Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therAβy for Alzheimer's disease: a Phase Ha, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7(9), 779-786 (2008).
51. Kessler H, Bayer TA, Bach D et al. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot Phase 2 clinical trial. J. Neural Transm. 115(8), 1181-1187 (2008).
52. Kessler H, Pajonk FG, Bach D et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot Phase II clinical trial. J. Neural Transm. 115(12), 1651-1659 (2008).
53. Squitti R, Rossini PM, Cassetta E et al. D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur.J. Clin. Invest. 32(1), 51-59 (2002)
54. Gonzalez C, Martin T, Cacho J et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 Aβolipoprotein E allele carriers. Eur. J. Clin. Invest. 29(7), 637-642 (1999).